A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
PSMA Therapy and Immunotherapy in Kidney Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- Status
- RECRUITING
- Phase
- PHASE3
129 Xenon Imaging in Patients Treated With Sotatercept
- Status
- RECRUITING
- Phase
- PHASE2
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Status
- RECRUITING
- Phase
- PHASE3
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens
- Status
- RECRUITING
- Phase
- PHASE4
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Non Primary HCMV Infection: Natural History and Immune Response
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
- Status
- RECRUITING
- Phase
- PHASE2
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
- Status
- RECRUITING
- Phase
- NA
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2